Template to add a clinical trial: Difference between revisions
Line 30: | Line 30: | ||
== Inclusion Criteria == | == Inclusion Criteria == | ||
PATIENTS: | PATIENTS: | ||
Revision as of 18:59, 2 June 2009
How to edit trial information: Log in, click on the word [edit] to the right of the section you would like to edit, type in the appropriate information, click save page at the bottom when you are done. The template is the minimum elements required by the World Health Organization. You can add additional sections. More help to add a trial here.
European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry
Study Acronym (The trial's abbreviation if there is one)
None reported
Dudek D, Siudak Z, Janzon M, Birkemeyer R, Aldama-Lopez G, Lettieri C, Janus B, Wisniewski A, Berti S, Olivari Z, Rakowski T, Partyka L, Goedicke J, Zmudka K; EUROTRANSFER Registry Investigators.
BACKGROUND: Abciximab is established as adjunct to primary percutaneous coronary intervention (PCI). Based on some smaller studies, ST-segment elevation myocardial infarction (STEMI) networks in various European countries have adopted the start of abciximab before transfer to the catheterization laboratory (cathlab) hospital as part of their routine treatment options. Although a recently published study did not reveal improved clinical outcome when starting abciximab before the cathlab, a potential benefit from such early administration, in particular in the setting of transfer networks, remains unclear and has been the subject of debate.
Patients with ST-Elevation MI
Study Phase (e.g. Phase I,II,III,IV) Study Phases are defined here
None reported
Natural History, Cross-Sectional, Defined Population, Prospective Study
Study Arms and How They Were Treated (Intervention) (Explanation here)
None reported
Primary Pre-Specified Endpoint
None reported
Secondary Endpoints
None reported
Inclusion Criteria
PATIENTS:
All consecutive STEMI patients >=18years arriving to the Cath Lab hospital (invasive facility center) from transfer.
Transfer with respect to this registry is defined as patients that reach the Cath Lab hospital:
transferred from a surrounding regional community hospitals that the Cath Lab hospital has an established referral pattern with or after being picked–up by an ambulance which is equipped/staffed to provide specific medical therapy (like prehospital thrombolysis or upstream abciximab). Usually these have a physician or specifically trained nurse on board.
Exclusion Criteria
None reported
Outcome: Primary endpoint (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)
None reported
Outcome: Secondary endpoint (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)
None reported
Outcome: Exploratory endpoints (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)
None reported
Outcome: Safety endpoints (Report both relative risk and absolute risk as well as number needed to harm if available)
None reported
Conclusions of the Investigators (Quote the investigators conclusions here)
None reported
Commentary, Discussion and Limitations of the Trial (Anyone can add comments)
None reported
Slides
None reported
Video Commentary
None reported
References (How to insert a reference)
None reported
External sites for further information (How to insert links)
None reported
Detailed information about the trial
Ages
__ years to ___ years
Gender (Indicate whether men, women or both were enrolled)
None reported
Accepts Healthy Volunteers (Answer yes or no)
None reported
Enrollment Period (Study start and end date)
None reported
Recruitment Status (explanation)
None reported
Enrollment (Total number of patients enrolled)
None reported
Study Sponsor (e.g. Investigator initiated or company name)
None reported (this may not have yet been ascertained)
Source of Data (Where is this data on this page coming from: publication, principal investigator, or co-investigator)
None reported
The content of the clinical trial wiki consists of fields that have been suggested by the World Health Organization and wwww.clinicaltrials.gov.